Literature DB >> 23184503

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.

A Laroni, D Brogi, V Milesi, L Abate, A Uccelli, Gl Mancardi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23184503     DOI： 10.1177/1352458512468498

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  11 in total

1.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

2.  Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Authors:  Per Soelberg Sorensen; Nils Koch-Henriksen; Thor Petersen; Mads Ravnborg; Annette Oturai; Finn Sellebjerg
Journal:  J Neurol       Date:  2014-04-12       Impact factor: 4.849

3.  Recurrence of disease activity after repeated Natalizumab withdrawals.

Authors:  Laura Ferrè; Lucia Moiola; Francesca Sangalli; Marta Radaelli; Valeria Barcella; Giancarlo Comi; Vittorio Martinelli
Journal:  Neurol Sci       Date:  2014-09-24       Impact factor: 3.307

Review 4.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

5.  Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Authors:  Luisa Klotz; Berit Grützke; Maria Eveslage; Michael Deppe; Catharina C Gross; Lucienne Kirstein; Anita Posevitz-Fejfar; Tilman Schneider-Hohendorf; Nicholas Schwab; Sven G Meuth; Heinz Wiendl
Journal:  BMC Neurol       Date:  2015-06-23       Impact factor: 2.474

Review 6.  An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.

Authors:  Barbara Kornek
Journal:  Patient Prefer Adherence       Date:  2015-05-19       Impact factor: 2.711

Review 7.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

Review 8.  Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Authors:  Ilya Ayzenberg; Robert Hoepner; Ingo Kleiter
Journal:  Ther Clin Risk Manag       Date:  2016-02-19       Impact factor: 2.423

9.  Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.

Authors:  Francesco Patti; Carmela Leone; Mario Zappia
Journal:  BMC Neurol       Date:  2015-12-07       Impact factor: 2.474

10.  Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

Authors:  Marianna Lo Re; Marco Capobianco; Paolo Ragonese; Sabrina Realmuto; Simona Malucchi; Paola Berchialla; Giuseppe Salemi; Antonio Bertolotto
Journal:  Neurol Ther       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.